Identification of estrogen receptor proteins in breast cancer cells using matrix‑assisted laser desorption/ionization time of flight mass spectrometry (Review)

Heger,Zbynek; Rodrigo,Miguel Angel Merlos; Krizkova,Sona; Zitka,Ondrej; Beklova,Miroslava; Kizek,Rene; Adam,Vojtech

doi:10.3892/ol.2014.1912

Identification of estrogen receptor proteins in breast cancer cells using matrix‑assisted laser desorption/ionization time of flight mass spectrometry (Review)

Authors:
- Zbynek Heger
- Miguel Angel Merlos Rodrigo
- Sona Krizkova
- Ondrej Zitka
- Miroslava Beklova
- Rene Kizek
- Vojtech Adam
View Affiliations

Affiliations: Department of Veterinary Ecology and Environmental Protection, Faculty of Veterinary Hygiene and Ecology, University of Veterinary and Pharmaceutical Sciences Brno, Brno CZ‑612 42, Czech Republic, Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Brno CZ‑613 00, Czech Republic
Published online on: February 26, 2014 https://doi.org/10.3892/ol.2014.1912
Pages: 1341-1344

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Estrogen receptors [ERs (subtypes α and β)], classified as a nuclear receptor super family, are intracellular proteins with an important biological role as the transcription factors for estrogen target genes. For ER‑induced transcription, an interaction must exist between ligand and coregulators. Coregulators may stimulate (coactivators) or inhibit (corepressors) transcription, following binding with a specific region of the gene, called the estrogen response element. Misbalanced activity of coregulators or higher ligand concentrations may cause increased cell proliferation, resulting in specific types of cancer. These are exhibited as overexpression of ER proteins. Breast cancer currently ranks first in the incidence and second in the mortality of cancer in females worldwide. In addition, 70% of breast tumors are ERα positive and the importance of these proteins for diagnostic use is indisputable. Early diagnosis of the tumor and its classification has a large influence on the selection of appropriate therapy, as ER‑positive tumors demonstrate a positive response to hormonal therapy. Matrix‑assisted laser desorption/ionization time of flight mass spectrometry (MALDI TOF MS) has been hypothesized to have great potential, as it offers reliable, robust and efficient analysis methods for biomarker monitoring and identification. The present review discusses ER protein analysis by MALDI TOF MS, including the crucial step of protein separation.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
3	Patani N, Martin LA and Dowsett M: Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer. 133:1–13. 2013. View Article : Google Scholar : PubMed/NCBI
4	Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar
5	Yang XR, Chang-Claude J, Goode EL, et al: Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 103:250–263. 2011. View Article : Google Scholar : PubMed/NCBI
6	Muss HB: Coming of age: breast cancer in seniors. Oncologist. 16(Suppl 1): S79–S87. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ma H, Wang Y, Sullivan-Halley J, et al: Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women’s contraceptive and reproductive experiences study. Cancer Res. 70:575–587. 2010.
8	Shubbar E, Helou K, Kovács A, et al: High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. BMC Cancer. 13:472013.
9	Tian W, Chen J, He H and Deng Y: MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications. Clin Transl Oncol. 15:335–342. 2013. View Article : Google Scholar : PubMed/NCBI
10	Ombra MN, Di Santi A, Abbondanza C, Migliaccio A, Avvedimento EV and Perillo B: Retinoic acid impairs estrogen signaling in breast cancer cells by interfering with activation of LSD1 via PKA. Biochim Biophys Acta. 1829:480–486. 2013. View Article : Google Scholar : PubMed/NCBI
11	Fasching PA, Heusinger K, Haeberle L, et al: Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 11:4862011. View Article : Google Scholar
12	Sharan S, Nikhil K and Roy P: Effects of low dose treatment of tributyltin on the regulation of estrogen receptor functions in MCF-7 cells. Toxicol Appl Pharmacol. 269:176–186. 2013. View Article : Google Scholar
13	Yan Y, Liu H, Wen H, et al: The novel estrogen receptor GPER regulates the migration and invasion of ovarian cancer cells. Mol Cell Biochem. 378:1–7. 2013. View Article : Google Scholar : PubMed/NCBI
14	Oh Y and Chung KC: Zinc finger protein 131 inhibits estrogen signaling by suppressing estrogen receptor α homo-dimerization. Biochem Biophys Res Commun. 430:400–405. 2013.PubMed/NCBI
15	Komm BS and Mirkin S: Evolution of the tissue selective estrogen complex (TSEC). J Cell Physiol. 228:1423–1427. 2013. View Article : Google Scholar : PubMed/NCBI
16	Cheng Q, Chang JT, Geradts J, et al: Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res. 14:R622012. View Article : Google Scholar
17	Coughlan N, Thillainadesan G, Andrews J, Isovic M and Torchia J: β-Estradiol-dependent activation of the JAK/STAT pathway requires p/CIP and CARM1. Biochim Biophys Acta-Mol Cell Res. 1833:1463–1475. 2013.
18	Sengupta S, Obiorah I, Maximov PY, Curpan R and Jordan VC: Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 169:167–178. 2013. View Article : Google Scholar
19	Levin ER: Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol. 19:1951–1959. 2005. View Article : Google Scholar : PubMed/NCBI
20	Pirman DA, Efuet E, Ding XP, et al: Changes in cancer cell metabolism revealed by direct sample analysis with MALDI mass spectrometry. PLoS One. 8:e613792013. View Article : Google Scholar
21	Cornett DS, Reyzer ML, Chaurand P and Caprioli RM: MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat Methods. 4:828–833. 2007. View Article : Google Scholar : PubMed/NCBI
22	Wang HS, Wu HM, Cheng BH, et al: Functional analyses of endometriosis-related polymorphisms in the estrogen synthesis and metabolism-related genes. PLoS One. 7:e473742012. View Article : Google Scholar
23	Srinivasan S, Nwachukwu JC, Parent AA, et al: Ligand-binding dynamics rewire cellular signaling via estrogen receptor-α. Nat Chem Biol. 9:326–332. 2013.PubMed/NCBI
24	Aust S, Horak P, Pils D, et al: The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer. BMC Cancer. 13:1152013. View Article : Google Scholar
25	Borjesson AE, Farman HH, Engdahl C, et al: The role of activation functions 1 and 2 of estrogen receptor-α for the effects of estradiol and selective estrogen receptor modulators in male mice. J Bone Miner Res. 28:1117–1126. 2013.
26	Zeng H, Wu JC, Bedford MT, et al: A TR-FRET-based functional assay for screening activators of CARM1. Chembiochem. 14:827–835. 2013. View Article : Google Scholar : PubMed/NCBI
27	Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, et al: Genotype in BRCA-associated breast cancers. Breast J. 19:87–91. 2013. View Article : Google Scholar : PubMed/NCBI
28	Jiang H, Teng R, Wang Q, et al: Transcriptional analysis of estrogen receptor alpha variant mRNAs in colorectal cancers and their matched normal colorectal tissues. J Steroid Biochem Mol Biol. 112:20–24. 2008. View Article : Google Scholar
29	Wang J, Li J, Fang R, Xie S, Wang L and Xu C: Expression of ERα36 in gastric cancer samples and their matched normal tissues. Oncol Lett. 3:172–175. 2012.
30	Tu BB, Lin SL, Yan LY, Wang ZY, Sun QY and Qiao J: ER-α36, a novel variant of estrogen receptor α, is involved in EGFR-related carcinogenesis in endometrial cancer. Am J Obstet Gynecol. 205:227.e1–e6. 2011.
31	Kammerer M, Gutzwiller S, Stauffer D, Delhon I, Seltenmeyer Y and Fournier B: Estrogen receptor α (ERα) and estrogen related receptor α (ERRα) are both transcriptional regulators of the Runx2-I isoform. Mol Cell Endocrinol. 369:150–160. 2013.
32	Gamucci T, Vaccaro A, Ciancola F, et al: Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol. 139:853–860. 2013. View Article : Google Scholar
33	Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP and Sherman ME: Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 13:1558–1568. 2004.PubMed/NCBI
34	Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS and Yde CW: Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat. 139:71–80. 2013.
35	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
36	Ramirez-Ardila DE, Helmijr JC, Look MP, et al: Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat. 139:39–49. 2013. View Article : Google Scholar : PubMed/NCBI
37	Hiscox S, Davies EL and Barrett-Lee P: Aromatase inhibitors in breast cancer. Maturitas. 63:275–279. 2009. View Article : Google Scholar
38	Hodgkinson VC, Agarwal V, El Fadl D, et al: Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. J Proteomics. 75:2745–2752. 2012. View Article : Google Scholar
39	Kim SI, Sohn J, Koo JS, Park SH, Park HS and Park BW: Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology. 79:324–330. 2010. View Article : Google Scholar : PubMed/NCBI
40	Haddock CL, Holtz B, Senzer N and Nemunaitis J: Applications of HPLC-MALDI-TOF MS/MS phosphoproteomic analysis in oncological clinical diagnostics. Curr Proteomics. 8:153–167. 2011. View Article : Google Scholar
41	Tangjitgamol S, Tanvanich S, Srijaipracharoen S and Manusirivithaya S: Expression of estrogen receptor, progesterone receptor, and Her-2/neu in primary and extra-corporeal endometrial cancer. Histol Histopathol. 28:787–794. 2013.PubMed/NCBI
42	Alkner S, Bendahl PO, Grabau D, et al: The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor. Ann Oncol. 24:1244–1252. 2013. View Article : Google Scholar
43	Seferina SC, Nap M, van den Berkmortel F, Wals J, Voogd AC and Tjan-Heijnen VC: Reliability of receptor assessment on core needle biopsy in breast cancer patients. Tumour Biol. 34:987–994. 2013. View Article : Google Scholar : PubMed/NCBI
44	Wik E, Ræder MB, Krakstad C, et al: Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res. 19:1094–1105. 2013.
45	Kinsella MD, Birdsong GG, Siddiqui MT, Cohen C and Hanley KZ: Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples. Diagn Cytopathol. 41:192–198. 2013.
46	Sang QX, Man YG, Sung YM, et al: Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis. Clin Exp Metastasis. 29:143–153. 2012. View Article : Google Scholar
47	Jin Y, Zhang X, Lu D, et al: Histopathological and proteomic analysis of hepatic tissue from adult male zebrafish exposed to 17β-estradiol. Environ Toxicol Pharmacol. 29:91–95. 2010.PubMed/NCBI
48	Pietrowska M, Marczak L, Polanska J, et al: Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer. J Transl Med. 7:602009. View Article : Google Scholar : PubMed/NCBI
49	Bouchal P, Dvorakova M, Scherl A, Garbis SD, Nenutil R and Vojtesek B: Intact protein profiling in breast cancer biomarker discovery: protein identification issue and the solutions based on 3D protein separation, bottom-up and top-down mass spectrometry. Proteomics. 13:1053–1058. 2013. View Article : Google Scholar
50	Nalvarte I, Schwend T and Gustafsson JA: Proteomics analysis of the estrogen receptor alpha receptosome. Mol Cell Proteomics. 9:1411–1422. 2010. View Article : Google Scholar : PubMed/NCBI
51	Atsriku C, Benz CC, Scott GK, Gibson BW and Baldwin MA: Quantification of cysteine oxidation in human estrogen receptor by mass spectrometry. Anal Chem. 79:3083–3090. 2007. View Article : Google Scholar : PubMed/NCBI
52	Cornett DS, Mobley JA, Dias EC, et al: A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol Cell Proteomics. 5:1975–1983. 2006. View Article : Google Scholar
53	Kabbage M, Trimeche M, Bergaoui S, et al: Calreticulin expression in infiltrating ductal breast carcinomas: relationships with disease progression and humoral immune responses. Tumour Biol. 34:1177–1188. 2013. View Article : Google Scholar
54	Castilla MÁ, Diaz-Martin J, Sarrió D, et al: MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One. 7:e477092012.PubMed/NCBI
55	Paramanik V and Thakur MK: Estrogen receptor β and its domains interact with casein kinase 2, phosphokinase C, and N-myristoylation sites of mitochondrial and nuclear proteins in mouse brain. J Biol Chem. 287:22305–22316. 2012.
56	Bovet C, Plet B, Ruff M, et al: Towards high-throughput identification of endocrine disrupting compounds with mass spectrometry. Toxicol In Vitro. 23:704–709. 2009. View Article : Google Scholar : PubMed/NCBI
57	Collodoro M, Lemaire P, Eppe G, et al: Identification and quantification of concentration-dependent biomarkers in MCF-7/BOS cells exposed to 17β-estradiol by 2-D DIGE and label-free proteomics. J Proteomics. 75:4555–4569. 2012.PubMed/NCBI
58	Lai TC, Chou HC, Chen YW, et al: Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis. J Proteome Res. 9:1302–1322. 2010. View Article : Google Scholar : PubMed/NCBI
59	Obazee O, Justenhoven C, Winter S, et al: Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant. Breast Cancer Res Treat. 138:543–548. 2013. View Article : Google Scholar : PubMed/NCBI